Table 2.
Clinicopathologic features of cHL cases stratified by clonal hematopoiesis distribution in the tissue
| Clonal hematopoiesis in cHL tissue | ||||
|---|---|---|---|---|
| N = 40 patients | Extensivea (n = 3) | Absent/nonextensive (n = 37) | P b | |
| Age | >60 years | 1 (33%) | 9 (24%) | 1 |
| <60 years | 2 (67%) | 28 (76%) | ||
| EBV status | EBV+ | 1 (33%) | 8 (22%) | 0.55 |
| EBV– | 2 (67%) | 29 (78%) | ||
| Histotype | Nodular sclerosis | 1 (33%) | 21 (57%) | 0.58c |
| Mixed cellularity | 2 (67%) | 12 (32%) | ||
| Other | 0 (0%) | 4 (11%) | ||
| Clinical stage | Early (≤ IIA) | 1 (33%) | 13 (37%)d | 1 |
| Advanced (≥ IIB) | 2 (67%) | 22 (63%)d | ||
| Outcome of first-line therapye | No progression | 0 (0%) | 24 (69%)f | 0.043 |
| Progression | 3 (100%) | 11 (31%)f | ||
| Follow-up in monthsg | 0–6–35 | 64 (median)g | 0.034 | |
| 0–149 (range)g | ||||
aExtensive: VAF ≥10%.
bBy Fisher exact test except for comparison of follow-up where t test was used.
cNodular sclerosis versus all other subtypes.
dClinical stage at diagnosis was not available for two patients (UPN26 and UPN40).
eABVD in all cases, with the following exceptions of little relevance: (i) COPP/ABV in pediatric patient UPN27, not showing clonal hematopoiesis and not progressing after first-line therapy; (ii) COPP without vincristine in elderly patient UPN41/case 3, whose outcome was not evaluable; and (iii) omission of bleomycin in 3/35 patients (UPN13, UPN25/case 4, and UPN30, all without extensive clonal hematopoiesis in the cHL tissue and all not progressing after first-line therapy). COPP/ABV stands for cyclophosphamide, vincristine sulfate, prednisone, procarbazine hydrochloride/doxorubicin hydrochloride, bleomycin, vinblastine sulfate.
fOutcome was not available for one patient (UPN40) and not evaluable in another patient (UPN41/case 3) who died early due to acute chemotherapy toxicity.
gFollow-up was not available for one patient (UPN40) and not evaluable in another (UPN41/case 3).